Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review

Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essent...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2021-12, Vol.68 (12), p.e29346-n/a
Main Authors: Liu, Lucy Y., Teng, Joyce M. C., Spunt, Sheri L., Strelo, Jenna L., Kwong, Bernice Y., Zaba, Lisa C.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Antineoplastic drugs
cancer
Child
cutaneous
Hematology
Humans
Immune Checkpoint Inhibitors
immunotherapy
Immunotherapy - adverse effects
Neoplasms - drug therapy
Neoplasms - etiology
oncodermatology
Oncology
Patients
pediatric
Pediatrics
Quality of Life
Skin
Systematic review
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essential to optimize ongoing cancer‐directed therapy and improve quality of life. This systematic review of published studies summarizes dermatologic toxicities to targeted anticancer treatments and immune checkpoint inhibitors.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29346